AU2018293729B9 - New salt of N-(2,6-diethylphenyl)-8-({4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide, its preparation and formulations containing it - Google Patents

New salt of N-(2,6-diethylphenyl)-8-({4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide, its preparation and formulations containing it Download PDF

Info

Publication number
AU2018293729B9
AU2018293729B9 AU2018293729A AU2018293729A AU2018293729B9 AU 2018293729 B9 AU2018293729 B9 AU 2018293729B9 AU 2018293729 A AU2018293729 A AU 2018293729A AU 2018293729 A AU2018293729 A AU 2018293729A AU 2018293729 B9 AU2018293729 B9 AU 2018293729B9
Authority
AU
Australia
Prior art keywords
tumors
lymphoma
cell
leukemia
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018293729A
Other languages
English (en)
Other versions
AU2018293729A1 (en
AU2018293729B2 (en
Inventor
Marina Caldarelli
Ilaria Candiani
Matteo D'anello
Germano D'arasmo
Massimo Zampieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of AU2018293729A1 publication Critical patent/AU2018293729A1/en
Assigned to NERVIANO MEDICAL SCIENCES S.R.L. reassignment NERVIANO MEDICAL SCIENCES S.R.L. Request for Assignment Assignors: LES LABORATOIRES SERVIER
Publication of AU2018293729B2 publication Critical patent/AU2018293729B2/en
Application granted granted Critical
Publication of AU2018293729B9 publication Critical patent/AU2018293729B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018293729A 2017-06-29 2018-06-28 New salt of N-(2,6-diethylphenyl)-8-({4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide, its preparation and formulations containing it Active AU2018293729B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305826.4 2017-06-29
EP17305826 2017-06-29
PCT/EP2018/067394 WO2019002454A1 (en) 2017-06-29 2018-06-28 NOVEL N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-YL] -2-METHOXYPHENYL} AMINO) -1-METHYL-4,5-DIHYDRO-1H SALT -PYRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING THE SAME

Publications (3)

Publication Number Publication Date
AU2018293729A1 AU2018293729A1 (en) 2020-01-23
AU2018293729B2 AU2018293729B2 (en) 2022-03-10
AU2018293729B9 true AU2018293729B9 (en) 2022-07-14

Family

ID=59313166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018293729A Active AU2018293729B9 (en) 2017-06-29 2018-06-28 New salt of N-(2,6-diethylphenyl)-8-({4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl}am ino)-1-methyl-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide, its preparation and formulations containing it

Country Status (18)

Country Link
US (3) US11160806B2 (enExample)
EP (1) EP3645535B1 (enExample)
JP (1) JP7141416B2 (enExample)
KR (1) KR102609333B1 (enExample)
CN (1) CN110896636B (enExample)
AR (1) AR112040A1 (enExample)
AU (1) AU2018293729B9 (enExample)
CA (1) CA3068357C (enExample)
CL (1) CL2019003848A1 (enExample)
EA (1) EA039764B1 (enExample)
ES (1) ES2900048T3 (enExample)
IL (1) IL271628B2 (enExample)
MA (1) MA49498A (enExample)
PL (1) PL3645535T3 (enExample)
SG (1) SG11201912651WA (enExample)
TW (1) TWI750393B (enExample)
UY (1) UY37778A (enExample)
WO (1) WO2019002454A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002962A1 (en) 2023-06-30 2025-01-02 Nerviano Medical Sciences S.R.L. Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma
WO2025021587A1 (en) 2023-07-21 2025-01-30 Nerviano Medical Sciences S.R.L. Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303891A1 (en) * 2008-06-26 2011-04-06 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazolines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303891A1 (en) * 2008-06-26 2011-04-06 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazolines

Also Published As

Publication number Publication date
TW201904971A (zh) 2019-02-01
CL2019003848A1 (es) 2020-07-10
CA3068357C (en) 2022-04-19
US11160806B2 (en) 2021-11-02
UY37778A (es) 2019-01-31
AU2018293729A1 (en) 2020-01-23
CA3068357A1 (en) 2019-01-03
US20220016122A1 (en) 2022-01-20
US20240350501A1 (en) 2024-10-24
AR112040A1 (es) 2019-09-11
PL3645535T3 (pl) 2022-03-21
BR112019027924A2 (pt) 2020-08-18
TWI750393B (zh) 2021-12-21
IL271628A (en) 2020-02-27
IL271628B2 (en) 2023-07-01
EP3645535A1 (en) 2020-05-06
KR102609333B1 (ko) 2023-12-01
JP2020525477A (ja) 2020-08-27
MA49498A (fr) 2021-05-26
EP3645535B1 (en) 2021-09-08
EA039764B1 (ru) 2022-03-11
IL271628B1 (en) 2023-03-01
CN110896636B (zh) 2022-07-19
AU2018293729B2 (en) 2022-03-10
US20200246339A1 (en) 2020-08-06
SG11201912651WA (en) 2020-01-30
JP7141416B2 (ja) 2022-09-22
KR20200020905A (ko) 2020-02-26
WO2019002454A1 (en) 2019-01-03
EA202090115A1 (ru) 2020-05-25
CN110896636A (zh) 2020-03-20
ES2900048T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
EP2734522B1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
CN111148745A (zh) Fgfr抑制剂的结晶形式及其制备方法
EP3091020B1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
KR20140009181A (ko) 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
CN111362949B (zh) 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
WO2024235289A1 (zh) 用于egfr蛋白降解的化合物及其用途
KR102516260B1 (ko) Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
BR112019027924B1 (pt) Fosfato de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2- metoxifenil}amino)-1-metil-4,5-di-hidro-1h-pirazolo[4,3-h]quinazolina-3- carboxamida, processo para a sua obtenção, composição farmacêutica, combinação e seus usos
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
WO2024255837A1 (zh) 一种enpp1抑制剂的晶型
TW202540122A (zh) Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
CN119119085A (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
CN120987978A (zh) 取代的螺环类抑制剂及其制备方法和应用
HK1192752B (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
HK1192752A (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
NZ620085B2 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NERVIANO MEDICAL SCIENCES S.R.L.

Free format text: FORMER APPLICANT(S): LES LABORATOIRES SERVIER

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished